Du L, Wang B, Wen J, Zhang N
Skin Res Technol. 2024; 30(4):e13663.
PMID: 38533746
PMC: 10966512.
DOI: 10.1111/srt.13663.
Zhu Z, Liu M, Wang J, Shu Z, Cao J
Curr Med Sci. 2024; 44(1):232-240.
PMID: 38393530
DOI: 10.1007/s11596-024-2828-8.
Zhang X, Lin J, Feng L, Ou M, Gong F
BMJ Open. 2023; 13(11):e074752.
PMID: 38000814
PMC: 10679995.
DOI: 10.1136/bmjopen-2023-074752.
Zhang X, Lin J, Ou M, Yan H, Liu S, Dai L
BMC Public Health. 2023; 23(1):1860.
PMID: 37749489
PMC: 10521450.
DOI: 10.1186/s12889-023-16758-6.
Boczar K, Beanlands R, Glassman S, Wang J, Zeng W, deKemp R
J Nucl Cardiol. 2023; 30(4):1642-1652.
PMID: 36754934
PMC: 10372102.
DOI: 10.1007/s12350-023-03204-8.
Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing.
Gracia-Cazana T, Bernal-Masferrer L, Morales-Callaghan A, Almenara-Blasco M, Gilaberte Y
Clin Cosmet Investig Dermatol. 2023; 16:221-229.
PMID: 36721838
PMC: 9884449.
DOI: 10.2147/CCID.S296544.
Long-term, durable, absolute Psoriasis Area and Severity Index and health-related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderate-to-severe plaque psoriasis.
Gooderham M, Pinter A, Ferris L, Warren R, Zhan T, Zeng J
J Eur Acad Dermatol Venereol. 2022; 36(6):855-865.
PMID: 35174556
PMC: 9314097.
DOI: 10.1111/jdv.18010.
Model-Based Meta-Analysis in Psoriasis: A Quantitative Comparison of Biologics and Small Targeted Molecules.
He H, Wu W, Zhang Y, Zhang M, Sun N, Zhao L
Front Pharmacol. 2021; 12:586827.
PMID: 34276352
PMC: 8281289.
DOI: 10.3389/fphar.2021.586827.
Direct comparison of risankizumab and fumaric acid esters in systemic therapy-naïve patients with moderate-to-severe plaque psoriasis: a randomized controlled trial.
Thaci D, Eyerich K, Pinter A, Sebastian M, Unnebrink K, Rubant S
Br J Dermatol. 2021; 186(1):30-39.
PMID: 33991341
PMC: 9291944.
DOI: 10.1111/bjd.20481.
Pharmacokinetics and tolerability of apremilast in healthy Korean adult men.
Huh K, Choi Y, Nissel J, Palmisano M, Wang X, Liu L
Clin Transl Sci. 2021; 14(4):1505-1511.
PMID: 33932093
PMC: 8301552.
DOI: 10.1111/cts.13013.
Epidemiological Variations in the Global Burden of Psoriasis, an Analysis With Trends From 1990 to 2017.
Peng C, Xu X, Chen W, Li X, Yi X, Ding Y
Front Med (Lausanne). 2021; 8:585634.
PMID: 33604344
PMC: 7884455.
DOI: 10.3389/fmed.2021.585634.
Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?.
Wright E, Yasmeen N, Malottki K, Sawyer L, Borg E, Schwenke C
Dermatol Ther (Heidelb). 2020; 11(1):181-220.
PMID: 33351178
PMC: 7858721.
DOI: 10.1007/s13555-020-00463-y.
Assessing the Short-Term Efficacy and Safety of Guselkumab for Moderate-to-Severe Plaque Psoriasis: Meta-Analysis of Randomized Controlled Trials.
Yang J, Wang Z, Zhang X
J Immunol Res. 2020; 2020:4975628.
PMID: 32724829
PMC: 7382754.
DOI: 10.1155/2020/4975628.
Psoriatic Disease in the US Latino Population: A Comprehensive Review.
Ashbaugh A, Ekelem C, Landaverde Y, Atanaskova Mesinkovska N
Am J Clin Dermatol. 2019; 21(2):265-274.
PMID: 31845122
DOI: 10.1007/s40257-019-00498-8.
Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response.
Sawyer L, Malottki K, Sabry-Grant C, Yasmeen N, Wright E, Sohrt A
PLoS One. 2019; 14(8):e0220868.
PMID: 31412060
PMC: 6693782.
DOI: 10.1371/journal.pone.0220868.
Kaempferol attenuates imiquimod-induced psoriatic skin inflammation in a mouse model.
Liu C, Liu H, Lu C, Deng J, Yan Y, Chen H
Clin Exp Immunol. 2019; 198(3):403-415.
PMID: 31407330
PMC: 6857081.
DOI: 10.1111/cei.13363.
Ghrelin protects against contact dermatitis and psoriasiform skin inflammation by antagonizing TNF-α/NF-κB signaling pathways.
Qu R, Chen X, Hu J, Fu Y, Peng J, Li Y
Sci Rep. 2019; 9(1):1348.
PMID: 30718736
PMC: 6362006.
DOI: 10.1038/s41598-018-38174-2.
Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response.
Sawyer L, Cornic L, Levin L, Gibbons C, Moller A, Jemec G
J Eur Acad Dermatol Venereol. 2018; 33(2):355-366.
PMID: 30289198
PMC: 6587780.
DOI: 10.1111/jdv.15277.
Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody.
Papp K, Gooderham M, Jenkins R, Vender R, Szepietowski J, Wagner T
Br J Dermatol. 2018; 180(6):1352-1360.
PMID: 30207587
PMC: 7379964.
DOI: 10.1111/bjd.17195.
Transcription Factor Retinoid-Related Orphan Receptor γt: A Promising Target for the Treatment of Psoriasis.
Tang L, Yang X, Liang Y, Xie H, Dai Z, Zheng G
Front Immunol. 2018; 9:1210.
PMID: 29899748
PMC: 5988853.
DOI: 10.3389/fimmu.2018.01210.
